Tango Therapeutics

74 articles about Tango Therapeutics

• Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024

  4/1/2024

  Tango Therapeutics, Inc. announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units to a new employee under Tango Therapeutics' 2023 Inducement Plan.

• Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

  3/18/2024

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.

• Tango Therapeutics to Participate in Upcoming March 2024 Investor Conferences

  3/6/2024

  Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.

• Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

  3/5/2024

  Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that one abstract has been selected for an oral minisymposium and seven abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.

• Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

  1/31/2024

  Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 11:30 AM EST.

• Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2024

  1/5/2024

  Tango Therapeutics, Inc. announced that, effective January 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 172,500 shares of its common stock and 26,000 restricted stock units to a new employee under Tango Therapeutics' 2023 Inducement Plan.

• Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers

  1/3/2024

  Tango Therapeutics, Inc. announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ cancers.

• Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

  11/13/2023

  Tango Therapeutics, Inc. announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology 28th Annual Meeting taking place November 15-19, 2023, in Vancouver, Canada.

• Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

  11/8/2023

  Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2023, and provided business highlights.

• Tango Therapeutics to Present at the Jefferies 2023 London Healthcare Conference

  11/7/2023

  Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 1:00 PM GMT.

• Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  9/18/2023

  Tango Therapeutics, Inc. today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.

• Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 4:00 PM ET.

• Tango Therapeutics Announces Updates to Its Board of Directors - August 29, 2023

  8/29/2023

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced changes to its Board of Directors.

• Tango Therapeutics Announces $80 million Private Placement Financing

  8/10/2023

  Tango Therapeutics, Inc. has agreed to sell approximately 15.5 million shares of its common stock in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private investment in public equity financing, at a per share price of $5.15.

• Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

  8/7/2023

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2023, and provided business highlights.

• Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

  7/24/2023

  Tango Therapeutics, Inc. today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.

• Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

  7/10/2023

  Tango Therapeutics, Inc. today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors. TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor previously granted Fast Track designation by the U.S. Food and Drug Administration.

• Tango Therapeutics to Participate in Upcoming June 2023 Investor Conferences

  6/1/2023

  Tango Therapeutics, Inc. announced that members of the management team are scheduled to participate in the following upcoming investor conferences in June.

• Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

  5/9/2023

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

• Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

  4/18/2023

  Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.